Structural features of low-molecular-weight heparins affecting their affinity to antithrombin

Summary

As part of a more extensive investigation on structural features of different low-molecular-weight heparins (LMWHs) that can affect their biological activities, Enoxaparin,Tinzaparin and Dalteparin were characterised with regards to the distribution of different chain length oligosaccharides as determined by size-exclusion (SE) chromatography, as well as their structure as defined by 2D-NMR spectra (HSQC). The three LMWHs were also fractionated into high affinity (HA) and no affinity (NA) pools with regards to their ability to bind antithrombin (AT).The HA fractions were further subfractionated and characterised. For the parent LMWHs and selected fractions,molecular weight parameters were measured using a SE chromatographic system with a triple detector (TDA) to obtain absolute molecular weights. The SE chromatograms clearly indicate that Enoxaparin is consistently richer in shorter oligosaccharides than Tinzaparin and Dalteparin. Besides providing the content of terminal groups and individual glucosamine and uronic acid residues with different sulfate substituents, the HSQC-NMR spectra permitted us to evaluate and correlate the content of the pentasaccharide, AT-binding sequence A-G-A*-I-A (AT-bs) through quantification of signals of the disaccharide sequence G-A*.Whereas the percent content of HA species is approximately the same for the three LMWHs, substantial differences were observed for the chain distribution of AT-bs as a function of length, with the AT-bs being preferentially contained in the longest chains of each LMWH. The above information will be useful in establishing structure-activity relationships currently under way. This study is therefore critical for establishing correlations between structural features of LMWHs and their AT-mediated anticoagulant activity.

Keywords

Low-molecular-weight heparin - structure - affinity fractionation - size fractionation - 2D-NMR

• References

• 1 Warkentin TE, Levine MN, Hirsh J. et al. Heparin induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1336.
• 2 Bara L, Samama MM. Pharmacokinetics of low molecular weight heparins. Acta Chir Scand 1988; 543: 65-72.
• 3 Handeland GF, Abildgaard U, Holm HA. et al. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol 1990; 39: 107-112.
• 4 Harenberg J. Pharmacology of low molecular weight heparins. Semin Thromb Hemost 1990; 16: 12-18.
• 5 Hirsh J. Low molecular weight heparin: a review of the results of recent studies of the treatment of venous thromboembolism and unstable angina. Circulation 1998; 98: 1575-1582.
• 6 Gray E, Mulloy B, Barrowcliffe TW. Heparin and low-molecular-weight-heparin. Thromb Haemost 2008; 99: 807-818.
• 7 Jeske WP, Walenga JM, Hoppensteadt DA. et al. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins. Semin Thromb Hemost 2008; 34: 74-85.
• 8 Casu B. Structure and active domains of heparin. In: Chemistry and Biology of Heparin and Heparan Sulfate. Oxford: Elsevier; 2005: 1-28.
• 9 Riesenfeld J, Thunberg L, Höök M. et al. Antithrombin-binding sequence of heparin. Location of essential N-sulfate groups. J Biol Chem 1981; 256: 2389-2394.
• 10 Casu B, Lindahl U. Structure and biological interactions of heparin and heparan sulfate. Adv Carbohydr Chem Biochem 2001; 57: 159-206.
• 11 Petitou M, Casu B, Lindahl U. 1976-1983, a critical period in the history of heparin. The discovery of the antithrombin binding site. Biochimie 2003; 85: 83-89.
• 12 Linhardt RJ, Gunay NS. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost 1999; 25 (Suppl. 03) 5-16.
• 13 Guerrini M, Guglieri S, Naggi A. et al. Low molecular weight heparins: structural differentiation by bidimensional nuclear magnetic resonance spectroscopy Semin Thromb Hemost 2007; 33: 478-487.
• 14 Mascellani G, Guerrini M, Torri G. et al. Characterization of di-and monosulfated, unsaturated heparin disaccharides with terminal N-sulfated 1,6-anhydro-β-D-glucosamine or N-sulfated 1,6-anhydro-β-D-mannosamine residues. Carbohydr Res 2007; 342: 835-842.
• 15 Guerrini M, Guglieri S, Casu B. et al. Antithrombin-binding octasaccharides and role of extensions of the active pentasaccharide sequence in the specificity and strength of interaction. J Biol Chem 2008; 283: 26662-26675.
• 16 Wagenvoord R, Al Dieri R, van Dedem G. et al. Linear diffusion of thrombin and factor Xa along the heparin molecule explains the effects of extended heparin chain lengths. Thromb Res 2008; 122: 237-245.
• 17 Petitou M, Imberty A, Duchaussoy P. et al. Experimental proof for the structure of a thrombin-inhibiting heparin molecule. Chemistry 2001; 07: 858-873.
• 18 de Kort M, Buijsman RC, van Boeckel CAA. Synthetic heparin derivatives as new anticoagulant drugs. Drug Discov Today 2005; 10: 769-779.
• 19 Jeske W, Fareed J. In vitro studies on the biochemistry and pharmacology of low molecular weight heparins. Semin Thromb Hemost 1999; 25: 27-33.
• 20 Bertini S, Bisio A, Torri G. et al. Molecular weight determination of heparin and dermatan sulfate by size exclusion chromatography with a triple detector array. Biomacromol 2005; 06: 168-173.
• 21 Guerrini M, Naggi A, Guglieri S. et al. Complex glycosaminoglycans: profiling substitution patterns by two-dimensional nuclear magnetic resonance spectroscopy. Anal Biochem 2005; 337: 35-47.
• 22 Goodger SJ, Robinson CJ, Murphy KJ. et al. Evidence that heparin saccharides promote FGF2 mitogenesis through two distinct mechanisms. J Biol Chem 2008; 283: 13001-13008.
• 23 Höök M, Björk I, Hopwood J. et al. Anticoagulant activity of heparin: separation of high-activity and lowactivity heparin species by affinity chromatography on immobilized antithrombin. FEBS Lett 1976; 66: 90-93.
• 24 Bitter T, Muir HM. Quantitative determination of uronic acids with m-hydroxydiphenyl. Anal Biochem 1962; 04: 330-334.
• 25 Iacomini M, Casu B, Guerrini M. et al. Linkage region sequences of heparins and heparan sulfates. Detection and quantification by NMR spectroscopy. Anal Biochem 1999; 274: 50-58.
• 26 Rodèn L, Ananth S, Campbell P. et al. Heparin - an introduction. In: Heparin and Related Polysaccharides. New York: Plenum Press; 1992: 1-20.
• 27 Kusche M, Torri G, Casu B. et al. Biosynthesis of heparin. Availability of 3-O-sulfation sites. J Biol Chem 1990; 265: 7292-7300.
• 28 Casu B, Torri G. Structural characterization of low molecular weight heparins. Semin Thromb Hemost 1999; 25 (Suppl. 03) 17-25.
• 29 Fareed J, Ma Q, Florian M. et al. Differentiation of low molecular-weight heparins: impact on the future of the management of thrombosis. Semin Thromb Hemost 2004; 30 (Suppl. 01) 89-104.